07:00 , Mar 9, 2009 |  BC Week In Review  |  Company News

Alloksys, Cevec, PharmaCell deal

The partners will use Cevec's human CAP cell line to develop a recombinant human alkaline phosphatase (rhuAP) protein to treat chronic diseases, including rheumatoid arthritis. Cevec will develop and produce the cell line and Alloksys...
07:00 , Sep 25, 2006 |  BC Week In Review  |  Clinical News

Alkaline phosphate: Phase II started

Alloksys began a Dutch Phase II trial in up to 150 patients undergoing coronary artery bypass graft (CABG) surgery. Alloksys Life Sciences B.V., Bunnik, the Netherlands   Product: Alkaline phosphate   Business: Inflammation   Molecular target: Not...